US equities |
GOOGL $283.82 ▼-12.64% GOOG $282.32 ▼-12.29% MU $934.27 ▼-4.98% MSFT $530.14 ▼-0.16% AMZN $243.79 ▼-4.25% META $624.52 ▲+1.96% NVDA $213.66 ▼-0.80% AAPL $348.91 ▲+1.48%
FinancialContent

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

6.670 +0.040 (+0.60%)
Delayed Quote Updated: 4:00 PM EDT, Oct 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Myriad Genetics, Inc. - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
News headline image
Datadog, Tripadvisor, Myriad Genetics, Planet Fitness And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 50 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
News headline image
Myriad Genetics Reports Third Quarter 2023 Financial Results; Generates Double-Digit Revenue Growth; Raises 2023 Revenue Guidance and Introduces 2024 Revenue Guidance
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 6, 2023 ↗
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million. 
Via Benzinga
News headline image
Earnings Outlook For Myriad Genetics ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 3, 2023 ↗
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million. 
Via Benzinga
News headline image
Preview: Myriad Genetics's Earnings ↗
 
Via Benzinga
News headline image
Myriad Genetics Appoints Sam Raha as Chief Operating Officer
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics to Release Third Quarter Financial Results on November 6, 2023
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer
From Myriad Genetics, Inc.
Via GlobeNewswire
Biotech Companies Make Further Progress in Promising Pancreatic Cancer Treatment Research
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:BNTX),(NASDAQ:SGEN),(NASDAQ:MYGN),(NASDAQ:ILMN) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials
Myriad can conduct prospective clinical trials using Illumina’s TruSight Oncology Comprehensive Investigational Use Only test 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Issues 2022 Environmental, Social and Governance Report
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer
Research will use Myriad’s high-definition MRD testing platform based on whole-genome sequencing 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Named to 2023 Best Workplaces in Health Care List by Fortune and Great Place To Work
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
New Myriad Genetics Survey Reveals Widespread Confusion and Misconceptions About Ovarian Cancer Screening Among a Majority of Women
Nearly three out of four women falsely believe a pap smear will reveal ovarian cancer presence 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics to Participate in Morgan Stanley Global Healthcare Conference
Myriad to also host Investor Day in South San Francisco in September 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics and Onsite Women’s Health Partner to Help More Women Understand Breast Cancer Risk
New collaboration increases access to genetic testing and can help identify patients with a high-risk for breast cancer 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics to Host Investor Day on September 19, 2023
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris®
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Intermountain Health and Myriad Genetics Participate in ComboMATCH
About Intermountain Health Headquartered in Utah with locations in seven states and additional operations across the western U.S., www.intermountainhealth.org is a nonprofit system of 33 hospitals, 385... 
Via PRUnderground
News headline image
Myriad Genetics and Intermountain Health Participate in ComboMATCH, a National Clinical Trial to Advance Cancer Treatment
ComboMATCH study uses genetic testing to match advanced cancer patients with targeted treatments 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Announces Enhancements to the GeneSight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Revenue and Adjusted EPS Guidance; Generates the Fourth Consecutive Quarter of Double-Digit Year-Over-Year Testing Volume Growth
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics to Release Second Quarter Financial Results on Aug. 3, 2023
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Announces Inclusion of Breast Density to MyRisk® with RiskScore® Breast Cancer Risk Assessment
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Announces New $90 Million Asset-Based Credit Facility
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Cramer Calls Tech Giant A 'Great' Long-Term Play, But In The Short Term It's Just 'Too Hot' ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said British American Tobacco p.l.c. (NYSE: BTI) is a "cheap stock. I’ll tell you, I actually like some of the things that Philip Morris International... 
Via Benzinga
News headline image
3 Gene Testing Stocks to Buy Before They Take Off ↗
The future of gene testing is bright thanks to an aging population. Here are three companies leading the industry. 
Via InvestorPlace
News headline image
Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform
Myriad to support MD Anderson researchers studying metastatic renal cell carcinoma treatment selection and response 
From Myriad Genetics, Inc.
Via GlobeNewswire
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >